VFA
CBIO

Virtus Fund Advisers’s Crescent Biopharma CBIO Stock Holding History

Virtus Fund Advisers’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$352K Buy
+210
New +$278K ﹤0.01% 398

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Virtus Fund Advisers's CBIO Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Crescent Biopharma (CBIO) in Q4 2017: 210 shares worth $352K. The stake represents ﹤0.01% of the portfolio and ranks #398 among its holdings.

80 funds tracked by Wall St. Rank hold CBIO as of Q4 2017.

  • Virtus Fund Advisers held 210 shares of Crescent Biopharma worth $352K as of Q4 2017.
  • Crescent Biopharma was a new Virtus Fund Advisers position in Q4 2017.
  • Crescent Biopharma made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #398 holding.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.